294863-06-2

Upstream product

• 69804-99-5 3-phenylpropanol methanesulfonate 
• 742105-17-5 1-[(R)-1-(tert-butyldimethylsilyloxy)-4-(5-hydroxy-1-methylindol-3-yl)-2-butyl]imidazole-4-carboxamide 
• 58630-07-2 5-(benzyloxy)-1-methyl-1H-indole-3-carbaldehyde 
• 122-97-4 3-Phenyl-1-propanol 
• 294863-17-5 3-(5-benzyloxy-1-methylindol-3-yl)propionaldehyde 
• 294863-18-6 5-benzyloxy-3-(3-butenyl)-1-methylindole 
• 742105-16-4 ethyl 3-(5-benzyloxy-1-methylindol-3-yl)acrylate 
• 294863-16-4 ethyl 3-(5-benzyloxy-1-methylindol-3-yl)propionate 
• 294863-19-7 (S)-4-(5-benzyloxy-1-methylindol-3-yl)butane-1,2-diol 
• 294863-20-0 (S)-4-(5-benzyloxy-1-methylindol-3-yl)-1-(tert-butyldimethylsilyloxy)butan-2-ol 
• 294862-78-5 1-[(R)-4-(5-benzyloxy-1-methylindol-3-yl)-1-(tert-butyldimethylsilyloxy)-2-butyl]imidazole-4-carboxamide 

Relevant academic research and scientific papers

Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors

We disclose herein optimization efforts around the novel, highly potent non-nucleoside adenosine deaminase (ADA) inhibitor, 1-[(R)-1-hydroxy-4-(6-(3-(1- methylbenzimidazol-2-yl)propionylamino)indol-1-yl)-2-butyl]imidazole-4- carboxamide 1 (Ki =

Heterocyclic compound, composition and method for inhibiting adenosine deaminase

Heterocyclic compounds of the following formula: wherein B is ?[wherein R1is hydrogen or lower alkyl; R2is hydrogen or lower alkyl; and X is hydrogen or hydroxy protective group], lower alkanoyl or hydroxyimino(lower)alkyl A is lower